It has recently been demonstrated that patients who develop chronic illness after prior exposure to water damaged buildings (WDB) and mold have the presence of mycotoxins, which can be detected in the urine. We hypothesized that the mold may be harbored internally and continue to release and/or produce mycotoxins which contribute to ongoing chronic illness. The sinuses are the most likely candidate as a site for the internal mold and mycotoxin production. In this paper, we review the literature supporting this concept.
References
[1]
Dennis, D.P. Chronic defective T-cells responding to superantigens, treated by reduction of fungi in the nose and air. Arch. Environ. Health 2003, 58, 433–451.
[2]
Dennis, D.P.; Roberson, D.; Curtis, L.; Black, J. Fungal exposure endocrinopathy with growth hormone deficiency; Dennis-Robertson syndrome. Toxicol. Ind. Health 2009, 25, 669–680, doi:10.1177/0748233709348266.
[3]
Rea, W.J.; Didriksen, N.; Simon, T.R.; Pan, Y.; Fenyves, E.J.; Griffiths, G. Effects of toxic exposure to mold and mycotoxins in building-related illnesses. Arch. Environ. Health 2003, 58, 399–405.
[4]
Campbell, A.; Thrasher, J.D.; Gray, M.R.; Vojdani, A. Mold and mycotoxins: Effects on the neurological and immune systems in humans. Adv. Appl. Microbiol. 2004, 55, 375–398, doi:10.1016/S0065-2164(04)55015-3.
[5]
Gray, M.R.; Thrasher, J.D.; Crago, R.; Madison, R.A.; Arnold, L.; Campbell, A.W.; Vojdani, A. Mixed mold mycotoxicosis: Immunological changes in humans following exposure to water damaged buildings. Arch. Environ. Health 2003, 58, 410–420.
[6]
Kilburn, K.H. Neurobehavioral and pulmonary impairment in 105 adults with indoor exposure to molds compared to 100 exposed to chemicals. Toxicol. Ind. Health 2009, 35, 681–692, doi:10.1177/0748233709348390.
[7]
Empting, L.D. Neurologic and neuropsychiatric syndrome features of mold and mycotoxin exposure. Toxicol. Ind. Health 2009, 25, 577–581, doi:10.1177/0748233709348393.
[8]
Park, J.H.; Cox-Ganser, J.M. Mold exposure and respiratory health in damp indoor environments. Front. Biosci. 2011, E3, 757–771, doi:10.2741/e284.
[9]
Fisk, W.J.; Eliseeva, E.A.; Mendell, M.J. Association of residential dampness and mold with respiratory tract infections and bronchitis: A meta-analysis. Environ. Health 2010, 9, 72, doi:10.1186/1476-069X-9-72.
[10]
Park, J.H.; Kreiss, K.; Cox-Ganser, J.M. Rhinosinusitis and mold as risk factors for asthma symptoms in occupants of a water-damaged building. Indoor Air 2012, 22, 396–404, doi:10.1111/j.1600-0668.2012.00775.x.
[11]
Tercelj, M.; Salobir, B.; Harlander, M.; Rylander, R. Fungal exposure in homes of patients with sarcoidosis—An environmental exposure study. Environ. Health 2011, 10, 8, doi:10.1186/1476-069X-10-8.
[12]
Laney, A.S.; Cragin, L.A.; Blevins, L.Z.; Sumner, A.D.; Cox-Ganser, J.M.; Kreiss, K.; Moffatt, S.G.; Lohff, C.J. Sarcoidosis, asthma and asthma-like symptoms among occupants of a historically water-damaged office building. Indoor Air 2009, 19, 83–90, doi:10.1111/j.1600-0668.2008.00564.x.
[13]
Chester, A.C.; Levine, P. Concurrent sick building syndrome and chronic fatigue syndrome: Epidemic neuromyasthenia revisited. Clin. Infect. Dis. 1994, 18, S43–S48, doi:10.1093/clinids/18.Supplement_1.S43.
[14]
Brewer, J.H.; Thrasher, J.D.; Straus, D.C.; Madison, R.A.; Hooper, D. Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins 2013, 5, 605–617, doi:10.3390/toxins5040605.
[15]
Polizzi, V.; Delmulle, B.; Adams, A.; Moretti, A.; Susca, A.; Picco, A.M.; Rosseel, Y.; Kindt, R.; van Bocxlaer, J.; de Kimpe, N.; et al. JEM Spotlight: Fungi, mycotoxins and microbial volatile organic compounds in mouldy interiors from water-damaged buildings. J. Environ. Monit. 2009, 11, 1849–1858, doi:10.1039/b906856b.
[16]
Smoragiewicz, W.; Cossette, B.; Boutard, A.; Kryzvstyniak, K. Trichothecene mycotoxins in the dust of ventilation systems in office buildings. Int. Arch. Occup. Environ. Health 1993, 65, 113–117, doi:10.1007/BF00405729.
[17]
T？ubel, M.; Sulyok, M.; Vishwanath, V.; Bloom, E.; Turunen, M.; J？rvi, K.; Kauhanen, E.; Krska, R.; Hyv？rinen, A.; Larsson, L.; et al. Co-occurrence of toxic bacterial and fungal secondary metabolites in moisture-damaged indoor environments. Indoor Air 2011, 21, 368–375, doi:10.1111/j.1600-0668.2011.00721.x.
[18]
Gottschalk, C.; Bauer, J.; Meyer, K. Detection of Satratoxin G and H in indoor air from a water-damaged building. Mycopatholgia 2008, 166, 103–107, doi:10.1007/s11046-008-9126-z.
[19]
Brasel, T.L.; Martin, J.M.; Carriker, C.G.; Wilson, S.C.; Straus, D.C. Detection of airborne Stachybotrys chartarum macrocyclic trichothecenes in the indoor environment. Appl. Environ. Microbiol. 2005, 71, 7376–7388.
[20]
Thrasher, J.D.; Crawley, S. The biocontaminants and complexity of damp indoor spaces: More than meets the eyes. Toxicol. Ind. Health 2009, 25, 583–615, doi:10.1177/0748233709348386.
[21]
Straus, D.C. Molds, mycotoxins, and sick building syndrome. Toxicol. Ind. Health 2009, 25, 617–635, doi:10.1177/0748233709348287.
[22]
Pestka, J.J.; Yike, I.; Dearborn, D.G.; Ward, M.D.; Harkema, J.R. Stachybotrys chartarum, trichothecenes mycotoxins, and damp building-related illness: New insights into a public health enigma. Toxicol. Sci. 2008, 104, 4–26, doi:10.1093/toxsci/kfm284.
[23]
Fukuda, K.; Strauss, S.E.; Hickie, I.; Sharpe, M.C.; Dobbins, J.G.; Komaroff, A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann. Intern. Med. 1994, 121, 953–959, doi:10.7326/0003-4819-121-12-199412150-00009.
[24]
Ostry, V.; Malir, F.; Ruprich, J. Producers and important dietary sources of ochratoxin A and citrinin. Toxins 2013, 5, 1574–1586, doi:10.3390/toxins5091574.
[25]
Thrasher, J.D.; Gray, M.R.; Kilburn, K.H.; Dennis, D.; Yu, A. A water-damaged home and health of occupants: A case study. J. Environ. Public Health 2012, doi:10.1155/2012/312836.
[26]
Dennis, D.P.; Atlanta Center for E.N.T. & Facial Plastic Center, Atlanta, GA, USA. 2010.
[27]
Ponikau, J.U.; Sherris, D.A.; Kern, E.B.; Homeburger, H.A.; Frigas, E.; Gaffey, T.A.; Roberts, G.D. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin. Proc. 1999, 74, 877–884.
[28]
Braun, H.; Buzina, W.; Freudenschuss, F.; Beham, A.; Stammberger, H. “Eosinophilic fungal rhinosinusitis”: A common disorder in Europe? Laryngoscope 2003, 113, 264–269, doi:10.1097/00005537-200302000-00013.
[29]
Murr, A.H.; Goldberg, A.N.; Pletcher, S.D.; Dillehay, K.; Wymer, L.J.; Vesper, S.J. Some chronic rhinosinusitis patients have elevated populations of fungi in their sinuses. Laryngoscope 2012, 122, 1438–1445, doi:10.1002/lary.23295.
[30]
El-Morsy, S.M.; Khafagy, Y.W.; El-Naggar, M.M.; Beih, A.A. Allergic fungal rhinosinusitis: Detection of fungal DNA in sinus aspirate using polymerase chain reaction. J. Layrngol. Otol. 2010, 124, 152–160, doi:10.1017/S0022215109991204.
[31]
Guo, C.; Ghadersohi, S.; Kephart, G.M.; Laine, R.A.; Sherris, D.A.; Kita, H.; Ponikau, J.U. Improving detection of fungi in eosinophilic mucin: Seeing what we could not see before. Otolaryngol. Head Neck Surg. 2012, 147, 943–949, doi:10.1177/0194599812451010.
[32]
Lewis, R.E.; Wiederhold, N.P.; Chi, J.; Han, X.Y.; Komanduri, K.V.; Kontoyiannis, D.P.; Prince, R.A. Detection of gliotoxin in experimental and human aspergillosis. Infect. Immun. 2005, 73, 636–637.
[33]
Korbel, R.; Bauer, J.; Gedek, B. Pathologico-anatomic and mycotoxicologic studies of aspergillosis in birds. Tierarit Prax 1998, 21, 134–139.
[34]
Bauer, J.; Gaareis, M.; Bott, A.; Gedek, B. Isolation of a mycotoxin (gliotoxin) from a bovine udder infected with Aspergillus fumigatus. J. Med. Vet. Mycol. 1989, 27, 45–50, doi:10.1080/02681218980000061.
[35]
Richard, J.L.; Debey, M.C. Production of gliotoxin during pathogenic state in turkey poults by Aspergillus fumigatus. Fresneius Mycopathol. 1995, 129, 111–115.
[36]
Matsumara, M.; Mori, T. Detection of aflatoxins in autopsied materials from a patient infected with Aspergillus flavus. Jpn. J. Med. Mycol. 1998, 39, 267–271.
[37]
Ohtomo, T.; Murkakoshi, S.; Sugiyama, S.; Kurata, H. Detection of aflatoxin B1 in silkworm larvae attached by an Aspergillus flavus isolate from a sericultural farm. Appl. Microbiol. 1975, 39, 1034–1035.
[38]
Bruns, S.; Seidler, M.; Albrecht, D.; Salvenmoser, S.; Remme, N.; Hertweck, C.; Brakhage, A.A.; Kniemeyer, O.; Müller, F.M. Functional genome profiling of Aspergillus fumigatus biofilm reveals enhanced production of the mycotoxin gliotoxin. Proteomics 2010, 10, 3097–3107, doi:10.1002/pmic.201000129.
Lieberman, S.M.; Jacobs, J.B.; Lebowitz, R.A.; Fitzgerald, M.B.; Crawford, J.; Feigenbaum, B.A. Measurement of mycotoxins in patients with chronic rhinosinusitis. Otolaryngol. Head Neck Surg. 2011, 145, 327–329, doi:10.1177/0194599811403891.
[41]
Hooper, D.G.; Bolton, V.E.; Guilford, F.T.; Straus, D.C. Mycotoxin detection in human samples from patients exposed to environmental molds. Int. J. Mol. Sci. 2009, 10, 1465–1475, doi:10.3390/ijms10041465.
[42]
Brasel, T.L.; Campbell, A.W.; Demers, R.E.; Ferguson, B.S.; Fink, J.; Vojdani, A.; Wilson, S.C.; Straus, D.C. Detection of trichothecene mycotoxins in sera from individuals exposed to Stachybotrys chartarum in indoor environments. Arch. Environ. Health 2004, 59, 317–323.
[43]
Layton, R.C.; Purdy, C.W.; Jumper, C.A.; Straus, D.C. Detection of macrocyclic trichothecene mycotoxins in a caprine (goat) tracheal instillation model. Toxicol. Ind. Health 2009, 25, 693–701, doi:10.1177/0748233709348275.
[44]
Gorny, R.L.; Reponen, T.L.; Willeke, K.; Schmechel, D.; Robine, E.; Boissier, M.; Grinshpun, S.A. Fungal fragments as indoor air biocontaminants. Appl. Environ. Microbiol. 2002, 68, 3522–3531, doi:10.1128/AEM.68.7.3522-3531.2002.
[45]
Gorny, R.L. Filamentous microorganisms and their fragments in indoor air—A review. Ann. Agric. Environ. Med. 2004, 11, 185–197.
[46]
Cho, S.-H.; Seo, S.-C.; Schmechel, D.; Grinshpun, A.G.; Reponen, T. Aerodynamic characteristics and respiratory deposition of fungal fragments. Atmos. Environ. 2005, 39, 5454–5465, doi:10.1016/j.atmosenv.2005.05.042.
[47]
Reponen, T.; Seo, S.-C.; Grimsley, F.; Lee, T.; Crawford, C.; Grinshpun, S.A. Fungal fragments in moldy houses: A field study in homes in New Orleans and Southern Ohio. Atmos. Environ. 2007, 41, 8140–8149, doi:10.1016/j.atmosenv.2007.06.027.
[48]
Gorny, R.L.; Lawniczek-Walczyk, A. Effect of two aerosololization methods on the release of fungal propagules from a contaminated agar surface. Ann. Agric. Environ. Med. 2012, 19, 279–284.
[49]
Scott, J. An Evolving Architecture: Past, Present & Future and Indoor Microbiology. In Proceedings of the Indoor Air Quality Association 15th Annual Meeting and Indoor Air Expos, Las Vegas, NV, USA, 5–7 March 2012.
[50]
Ponikau, J.U.; Sherris, D.A.; Hirohito, K.; Kern, E.B. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J. Allergy Clin. Immunol. 2002, 110, 862–866, doi:10.1067/mai.2002.130051.
[51]
Ponikau, J.U.; Sherris, D.A.; Weaver, A.; Kita, H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial. J. Allergy Clin. Immunol. 2005, 115, 125–131, doi:10.1016/j.jaci.2004.09.037.
[52]
Kern, E.B.; Sherris, D.; Stergiou, A.M.; Katz, L.; Rosenblatt, L.C.; Ponikau, J. Diagnosis and treatment of chronic rhinosinusitis: A focus on intranasal Amphotericin B. Ther. Clin. Risk Manag. 2007, 3, 319–325, doi:10.2147/tcrm.2007.3.2.319.
[53]
Chakrabarti, A.; Denning, D.W.; Ferguson, B.J.; Ponikau, J.; Buzina, W.; Kita, H.; Marple, B.; Panda, N.; Vlaminck, S.; Kauffmann-Lacroix, C.; et al. Fungal rhinosinusitis: A categorization and definitional schema addressing current controversies. Laryngoscope 2009, 119, 1809–1818, doi:10.1002/lary.20520.
[54]
Siddiqui, A.; Shah, A.A.; Bashir, S.H. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: Clinical spectrum and outcome of 25 cases. Neurosurgery 2004, 44, 602–613, doi:10.1227/01.NEU.0000134597.94269.48.
[55]
Gosepath, J.; Brieger, J.; Vlachtsis, K.; Mann, W.J. Fungal DNA is present in tissue specimens of patients with chronic rhinosinusitis. Am. J. Pathol. 2004, 18, 9–13.
[56]
Gray, M.R.; Progressive Health Care Group, Benson, AZ, USA. Personal communication, 2012.
Geronikaki, A.; Fesatidou, M.; Kartsey, V.; Macaey, F. Synthesis and biological evaluation of potent antifungal agents. Curr. Top. Med. Chem. 2013, 13, 2684–2733.
[59]
Kidane, Y.H.; Lawrence, C.; Murali, T.M. Computational approaches for discovery of common immunomodulators in fungal infections: Towards broad-spectrum immunotherapeutic interventions. BMC Microbiol. 2013, 13, doi:10.1186/1471-2180-13-224.
[60]
Foreman, A.; Psaltis, A.J.; Tan, L.W.; Wormald, P.J. Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am. J. Rhinol. Allergy 2009, 23, 556–561.
[61]
Pintucci, J.P.; Corno, S.; Garotta, M. Biofilms and infections of the upper respiratory tract. Eur. Rev. Med. Pharmacol. Sci. 2010, 14, 683–690.
[62]
Singhal, D.; Baker, L.; Wormold, P.J.; Tan, L.W. Aspergillus fumigatus biofilm on primary human sinonasal epithelial culture. Am. J. Rhinol. Allergy 2011, 25, 219–225, doi:10.2500/ajra.2011.25.3622.
[63]
Rini, J.F.; Grant, I.H. Neurological Disease after Mold Exposure, Immune Risks & Response to Biofilm-Focused Antifungal Therapy. In Proceedings of the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, San Francisco, CA, USA, 9–12 September 2013.
[64]
Ramage, G.; Rajendran, R.; Sherry, L.; Williams, C. Fungal biofilm resistance. Int. J. Microbiol. 2012, 2012, 528521:1–528521:14.
[65]
Fey, P.D. Modality of bacterial growth presents unique targets: How do we treat biofilm-mediated infections. Curr. Opin. Microbiol. 2010, 13, 610–615, doi:10.1016/j.mib.2010.09.007.
[66]
Foreman, A.; Wormald, P.J. Different biofilms, different disease? A clinical outcomes study. Laryngoscope 2010, 120, 1701–1706, doi:10.1002/lary.21024.
[67]
Loussert, C.; Schmitt, C.; Prévost, M.C.; Balloy, V.; Fadel, E.; Philippe, B.; Kauffmann-Lacroix, C.; Latjé, J.P.; Beauvais, A. The in vivo biofilm composition of Aspergillus fumigatus. Cell. Microbiol. 2010, 12, 405–410, doi:10.1111/j.1462-5822.2009.01409.x.
[68]
Beauvais, A.; Schmidt, C.; Guadagnini, S.; Roux, P.; Perret, E.; Henry, C.; Paris, S.; Mallet, A.; Prévost, M.C.; Latejé, J.C. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell. Microbiol. 2007, 9, 1588–1600, doi:10.1111/j.1462-5822.2007.00895.x.
Gibbons, J.G.; Beauvais, A.; Beau, R.; McGary, L.; Latgé, J.P.; Rokas, A. Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus. Eukaryot. Cell 2012, 11, 68–78, doi:10.1128/EC.05102-11.
[71]
Shopova, I.; Bruns, S.; Thywissen, A.; Kniemeyer, O.; Brakhage, A.A.; Hillmann, F. Extrinsic extracellular DNA leads to biofilm formation and colocalizes with matrix polysaccharides in the human pathogenic fungus Aspergillus fumigatus. Front. Microbiol. 2013, 4, 141.
[72]
Muller, F.M.; Seider, M.; Beauvais, A. Aspergillus fumigatus in the clinical setting. Med. Mycol. 2011, 49 (Suppl. 1), S96–S100, doi:10.3109/13693786.2010.502190.
[73]
Kaur, S.; Singh, S. Biofilm formation by Aspergillus fumigatus. Med. Mycol. 2013. in press.
[74]
Boase, D.; Jervis-Bardy, J.; Cieland, E.; Pant, H.; Tan, L.; Wormald, P.J. Bacterial-induced epithelial damage promotes fungal biofilm formation in a sheep model of sinusitis. Int. Forum Allergy Rhinol. 2013, 3, 341–348, doi:10.1002/alr.21138.
[75]
Boase, S.; Valentine, R.; Singhal, D.; Tan, L.W.; Wormald, P.J. A sheep model to investigate the role of fungal biofilms in sinusitis: Fungal and bacterial synergy. Int. Forum Allergy Rhinol. 2011, 1, 340–347, doi:10.1002/alr.20066.
[76]
Tan, N.C.; Tran, H.B.; Foreman, A.; Jardeleza, C.; Vreudge, S.; Wormold, P.J. Identifying intracellular Staphylococcus aureus in chronic rhinosinusitis: A direct comparison of techniques. Am. J. Rhinol. Allergy 2012, 26, 444–449, doi:10.2500/ajra.2012.26.3822.
[77]
Biel, M.A.; Brown, C.A.; Levinson, R.M.; Garvis, G.E.; Paisner, H.M.; Sigel, M.E.; Tedford, T.M. Evaluation of the microbiology of chronic maxillary sinusitis. Ann. Otol. Rhinol. Laryngol. 1998, 107, 942–945.
[78]
Aral, M.; Kele？, E.; Okur, E.; Alpay, H.C.; Yilmaz, M. The pathogenicity and antibiotic resistance of coagulase-negative Staphylococci isolated from the maxillary and ethmoid sinuses. Rhinology 2004, 42, 131–136.
[79]
Aral, M.; Keles, E.; Kaygusuz, I. The microbiology of ethmoid and maxillary sinuses in patients with chronic rhinosinusitis. Am. J. Otolaryngol. 2003, 24, 163–168, doi:10.1016/S0196-0709(02)32420-7.
[80]
O’Gara, J.P.; Humphreys, H. Staphylococcus epidermidis biofilms: Importance and implications. J. Med. Microbiol. 2001, 50, 582–587.
[81]
Mack, D.; Haeder, M.; Siemssen, N.; Laufs, R. Association of biofilm production of coagulase-negative Staphylococci with expression of a specific polysaccharide intracellular adhesion. J. Infect. Dis. 1996, 174, 881–884, doi:10.1093/infdis/174.4.881.
[82]
Uren, B.; Psaltis, A.; Wormold, P.J. Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. Laryngoscope 2008, 118, 1677–1680, doi:10.1097/MLG.0b013e31817aec47.
[83]
Ebbens, F.A.; Scadding, G.K.; Badia, L.; Hellings, P.W.; Jorissen, M.; Mullol, J.; Cardesin, A.; Bachert, C.; van Zele, T.P.; Dijkgraaf, M.G.; et al. Amphotericin B nasal lavages: Not a solution for patients with chronic rhinosinusitis. J. Allergy Clin. Immunol. 2006, 118, 1149–1156, doi:10.1016/j.jaci.2006.07.058.
[84]
Mowat, E.; Butcher, J.; Lang, S.; Williams, C.; Ramage, G. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J. Med. Microbiol. 2007, 56, 1205–1212, doi:10.1099/jmm.0.47247-0.
[85]
Mowat, E.; Lang, S.; Williams, C.; McCulloch, E.; Jones, B.; Ramage, G. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 2008, 62, 1281–1284, doi:10.1093/jac/dkn402.
[86]
Venkatesh, M.; Rong, L.; Raad, I.; Versalovic, J. Novel synergisitic antibiofilm combinations for salvage of infected catheters. J. Med. Microbiol. 2009, 58, 936–944.
